-

HMBL Investor Alert: Robbins LLP Reminds Shareholders of Class Action Against HUMBL Inc. (HMBL)

SAN DIEGO--(BUSINESS WIRE)--The Class: Shareholder rights law firm Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired HUMBL, Inc. (OTC: HMBL) common stock and/or the unregistered HUMBLE TX securities between November 21, 2020 and May 19, 2022. The complaint alleges violations of the Securities Act of 1933 and Securities Exchange Act of 1934. HUMBL is a mobile financial services company that offers: (i) a mobile app that allows peers, consumers, and merchants to connect; (ii) a mobile marketplace that allows consumers and merchants to connect more seamlessly in the digital economy; and (iii) financial products and services, targeted for simplified investing on the blockchain.

If you would like more information about HUMBL, Inc.'s misconduct, click here.

What is this Case About: HUMBL, Inc. (HMBL) Misled Investors Regarding its Business Prospects

According to the complaint, HUMBL began trading publicly on November 12, 2020, after a reverse merger with Tesoro Enterprises, Inc. During the class period, defendants made false and misleading statements. Specifically, they failed to disclose that the HUMBL Pay App did not have the basic functionality promised to investors and that several of the Company's hyped international business partnerships had a very low chance of contributing material revenues to the Company's bottom line. Defendants also sold a series of highly speculative unregistered securities called BLOCK Exchange Traded Index ("ETXs") products. These products purported to "simplify digital asset investing" for customers seeking exposure to cryptocurrency investments. In reality, they were unregistered securities that were collateralized by a variety of highly speculative and risky digital assets.

On April 25, 2022, the price of the Humbl common stock hit a low of $0.11 per share, down from a price high of $6.84 during the class period, which it has not been able to recover. Likewise, the price of BLOCK ETX has dropped over 87% from its height during the Class Period and has not recovered.

Next Steps: If you acquired shares of HUMBL, Inc. (HMBL) common stock and/or the unregistered HUMBLE TX securities between November 21, 2020 and May 19, 2022, you have until July 19, 2022, to ask the court to appoint you lead plaintiff for the class. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery.

All representation is on a contingency fee basis. Shareholders pay no fees or expenses.

Contact us to learn more:

Aaron Dumas
(800) 350-6003
adumas@robbinsllp.com
Shareholder Information Form

About Robbins LLP: A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002. To be notified if a class action against HUMBL Inc. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Aaron Dumas
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
adumas@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

Robbins LLP

OTC Pink:HMBL

Release Summary
HUMBL, Inc. (HMBL) Misled Investors Regarding its Business Prospects
Release Versions
$Cashtags

Contacts

Aaron Dumas
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
adumas@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

More News From Robbins LLP

Investor Notice: Robbins LLP Informs Investors of the Vistagen Therapeutics, Inc. Securities Class Action

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs investors that a class action was filed on behalf of all investors who purchased or otherwise acquired Vistagen Therapeutics, Inc. (NASDAQ: VTGN) common stock between April 1, 2024 and December 16, 2025. Vistagen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for neuropsychiatric and neurological disorders. For more information, submit a form, email attorney Aaron Dumas...

Investor Notice: Robbins LLP Informs Investors of the Securities Class Action Against Oracle Corporation

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs investors that a class action was filed on behalf of all persons and/or entities who purchased or otherwise acquired Oracle Corporation (NYSE: ORCL) Senior Notes issued pursuant to the Shelf Registration Statement filed with the SEC on March 15, 2024, and as supplemented on September 25, 2025. Oracle is an Austin, Texas-based company that sells database software, enterprise applications, and cloud infrastructure and hardware. For more information,...

Investor Notice: Robbins LLP Informs Investors of the Smart Digital Group Limited Securities Class Action

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Smart Digital Group Limited (NASDAQ: SDM) securities between May 5, 2025 and September 26, 2025. Smart Digital, together with its subsidiaries, provides internet media, business planning and consulting, event planning and execution, and software customization and marketing services in Mainland China and Macau. For more information, submit a fo...
Back to Newsroom